AIG
BCRX icon

American International Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

American International Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-93,415
Closed -$475K – 315
2024
Q1 		$475K Sell
93,415
-802
-0.9% -$4.51K ﹤0.01% 1684
2023
Q4 		$564K Sell
94,217
-381
-0.4% -$2.21K ﹤0.01% 1596
2023
Q3 		$670K Buy
94,598
+3,364
+4% +$24.2K ﹤0.01% 1444
2023
Q2 		$642K Buy
91,234
+1,712
+2% +$13.7K ﹤0.01% 1494
2023
Q1 		$747K Buy
89,522
+1,782
+2% +$17.2K ﹤0.01% 1391
2022
Q4 		$1.01M Sell
87,740
-320
-0.4% -$3.99K 0.01% 1200
2022
Q3 		$1.11M Buy
88,060
+1,244
+1% +$16K 0.01% 1130
2022
Q2 		$919K Sell
86,816
-2,570
-3% -$26.5K 0.01% 1248
2022
Q1 		$1.45M Sell
89,386
-6,292
-7% -$101K 0.01% 1142
2021
Q4 		$1.32M Sell
95,678
-1,637
-2% -$21.7K 0.01% 1260
2021
Q3 		$1.4M Sell
97,315
-2,312
-2% -$36.5K 0.01% 1236
2021
Q2 		$1.57K Sell
99,627
-3,325
-3% -$45.2K 0.01% 1251
2021
Q1 		$1.05K Buy
102,952
+272
+0.3% +$2.81K ﹤0.01% 1431
2020
Q4 		$765 Sell
102,680
-2,946
-3% -$15.2K ﹤0.01% 1539
2020
Q3 		$363K Buy
105,626
+11,287
+12% +$48.4K ﹤0.01% 1768
2020
Q2 		$450K Buy
94,339
+3,300
+4% +$13.2K ﹤0.01% 1653
2020
Q1 		$182K Sell
91,039
-1,703
-2% -$4.69K ﹤0.01% 1954
2019
Q4 		$320K Buy
92,742
+23,208
+33% +$58.4K ﹤0.01% 1943
2019
Q3 		$199K Sell
69,534
-484
-0.7% -$1.5K ﹤0.01% 2166
2019
Q2 		$265K Buy
70,018
+436
+0.6% +$2.62K ﹤0.01% 2051
2019
Q1 		$566K Sell
69,582
-2,254
-3% -$19.3K ﹤0.01% 1632
2018
Q4 		$580K Sell
71,836
-554
-0.8% -$4.31K ﹤0.01% 1581
2018
Q3 		$552K Buy
72,390
+8,236
+13% +$55.3K ﹤0.01% 1828
2018
Q2 		$368K Buy
64,154
+1,520
+2% +$8.37K ﹤0.01% 2019
2018
Q1 		$299K Sell
62,634
-3,368
-5% -$17.3K ﹤0.01% 2023
2017
Q4 		$324K Buy
66,002
+12,317
+23% +$59.7K ﹤0.01% 2035
2017
Q3 		$281K Buy
53,685
+4,014
+8% +$20.6K ﹤0.01% 2090
2017
Q2 		$276K Buy
49,671
+4,441
+10% +$27.1K ﹤0.01% 2084
2017
Q1 		$380K Buy
45,230
+2,989
+7% +$20.8K ﹤0.01% 1785
2016
Q4 		$267K Sell
42,241
-109
-0.3% -$567 ﹤0.01% 2005
2016
Q3 		$187K Buy
42,350
+64
+0.2% +$256 ﹤0.01% 2214
2016
Q2 		$120K Sell
42,286
-2,688
-6% -$8.35K ﹤0.01% 2477
2016
Q1 		$127K Buy
44,974
+500
+1% +$2.22K ﹤0.01% 3205
2015
Q4 		$458K Sell
44,474
-674
-1% -$6.7K ﹤0.01% 2102
2015
Q3 		$515K Buy
45,148
+300
+0.7% +$4K ﹤0.01% 1994
2015
Q2 		$670K Sell
44,848
-1,564
-3% -$17.8K ﹤0.01% 1913
2015
Q1 		$419K Sell
46,412
-1,200
-3% -$12.4K ﹤0.01% 2306
2014
Q4 		$579K Sell
47,612
-543
-1% -$6K ﹤0.01% 2002
2014
Q3 		$471K Buy
48,155
+1,315
+3% +$16.1K ﹤0.01% 2200
2014
Q2 		$597K Buy
46,840
+45,840
+4,584% +$446K ﹤0.01% 2012
2014
Q1 		$10.6K Sell
1,000
-2,500
-71% -$26.7K ﹤0.01% 4397
2013
Q4 		$26.6K Hold
3,500
– – ﹤0.01% 4025
2013
Q3 		$25.5K Sell
3,500
-33,866
-91% -$172K ﹤0.01% 3995
2013
Q2 		$57.9K Buy
+37,366
New +$64.5K ﹤0.01% 3509

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

American International Group's BCRX Position: Q2 2024 in Review

American International Group sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 93,415 shares — an estimated $475K sold.

American International Group first reported a position in BCRX in Q2 2013 and held it in 44 quarters. The position peaked at $1.45M in Q1 2022. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • American International Group reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • American International Group sold 93,415 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $475K.
  • American International Group first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 44 quarters.
  • American International Group's BioCryst Pharmaceuticals position peaked at $1.45M in Q1 2022.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.